Myelodysplastic syndromes (MDS)

被引：1

作者：

Burgstaller S. ^{[1
]}

机构：

[1] Abteilung für Innere Medizin IV, Klinikum Wels-Grieskirchen, Grieskirchnerstr. 42, Wels

来源：

memo - Magazine of European Medical Oncology | 2014年 / 7卷 / 3期

关键词：

ASH; 2013; Highlights; Myelodysplastic syndrome;

D O I：

10.1007/s12254-014-0158-4

中图分类号：

学科分类号：

摘要：

Myelodysplastic syndromes (MDS) are a heterogeneous group of diseases characterized by ineffective haematopoiesis and cytopenias in peripheral blood. Transformation into acute myeloid leukaemia is a common complication of MDS. Life expectancy varies between nearly normal and early death. MDS were an important issue at last year's annual meeting of the American Society of Hematology. Like in the years before, the majority of contributions dealt with preclinical aspects. In addition to that, several interesting clinical studies regarding diagnosis and treatment were presented. © 2014 Springer-Verlag Wien.

引用

页码：134 / 137

页数：3

共 23 条

[1]

Bennet J.M., Catovsky D., Daniel M.T., Proposals for the classification of the myelodysplastic syndromes, Br J Haematol, 51, pp. 189-199, (1982)

[2]

Greenberg P., Cox C., Lebeau M.M., International scoring system for evaluating prognosis in myelodysplastic syndromes, Blood, 89, pp. 2079-2088, (1997)

[3]

Greenberg P., Tuechler H., Schanz J., Revised international prognostic scoring system for myelodysplastic syndromes, Blood, 120, pp. 2454-2465, (2012)

[4]

Font P., Loscertales J., Soto C., Et al., Inter-observer discordance with the diagnosis of myelodysplastic syndromes with less than 5∈% bone marrow blasts: Unilineage vs. Multilineage dysplasia and repurducibility of the threshold of 2∈ % blasts, Blood, 122, (2013)

[5]

Nagata Y., Grossmann V., Okuno Y., Et al., Landscape of genetic lesions in 944 patients with myelodysplastic syndromes, Blood., (2013)

[6]

Fenaux P., Mufti G.J., Hellstrom-Lindberg E., Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher risk myelodysplastic syndromes: A randomised, open-label phase III study, Lancet Oncol, 10, pp. 223-232, (2009)

[7]

Prebet T., Gore D.S., Esterni B., Gardin C., Itzykson R., Thepot S., Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure, J Clin Oncol, 29, pp. 475-483, (2011)

[8]

Ades L., Guerci-Bresler A., Makhoul P.C., Et al., A phase II study of the efficacy and safety of an intensified schedule of azacitidine (AZA) in intermediate-2 and high risk MDS patients, Blood, (2013)

[9]

Garcia-Manero G., Savona M., Gore S.D., Et al., Hematologic response to oral azacitidine (CC-486) in subjects with WHO-defined RAEB-1 or RAEB-2 myelodysplastic syndromes (MDS), Blood, (2013)

[10]

Haase D., Germing U., Schanz J., New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: Evidence from a core dataset of 2124 patients, Blood, 110, pp. 4385-4395, (2007)

← 1 2 3 →